Policy / Pricing Most patients “won’t see benefit” with Alzheimer’s drugs PharmaphorumA review of clinical data on amyloid-targeting Alzheimer's therapies has found absent or trivial efficacy, but is facing pushback from some experts.Policy / PricingNeuroscienceRead full story pharminent April 16, 2026 (Last updated: April 16, 2026) Pharmaphorum A review of clinical data on amyloid-targeting Alzheimer’s therapies has found absent or trivial efficacy, but is facing pushback from some experts. Policy / PricingNeuroscienceRead full story Please leave this field emptySign up to receive free daily digest Check your inbox or spam folder to confirm your subscription. Post navigation Previous: Terremoto wins $108m in Series C to drive cancer and rare disease programmesNext: Beeline raises $300m for BMS drugs, and other biofinancings Related Stories Policy / Pricing Decoding Medicare Advantage Coding Intensity pharminent July 1, 2026 Policy / Pricing UK partners with Eli Lilly on obesity plan pharminent June 29, 2026 Policy / Pricing EFPIA report adds to pressures on EU drug pricing policy pharminent June 24, 2026
